Bacillus Calmette-Guerin
High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLCvaccinePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the High-risk Non-muscle Invasive Bladder Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Merck Sharp & Dohme LLC | Phase 3 | B |
Tyra-300 Tyra Biosciences, Inc | Phase 1/2 | CCC |
Polio/Rhinovirus Recombinant Istari Oncology, Inc. | Phase 1/2 | CC |
Same molecule, other indications
Bacillus Calmette-Guerin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →